Trill Impact, the firm that last year raised a debut fund of €900 million, has unveiled two investments in the last week, including its first venture capital deal. The firm led an SKr240 million (€43 million; $46 million) funding round in Swedish late-stage biopharmaceutical company Cinclus Pharma.
The company is developing linaprazan glurate, which could be used in the treatment of severe stomach acid-related disorders. “We see this as a great example of a company where commercial opportunity and impact go hand in hand,” said Nina Rawal, partner and co-head of ventures, in a statement.
Trill has also acquired a majority stake in Raksystems, which offers building inspections and services, “green building services” and related renovation and new construction projects. Press release here.